Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states

被引：0
|
作者：
T Yoshida
Y Ozawa
T Kimura
Y Sato
G Kuznetsov
S Xu
M Uesugi
S Agoulnik
N Taylor
Y Funahashi
J Matsui
机构：
[1] Discovery Biology,
[2] Oncology Product Creation Unit,undefined
[3] Eisai Co.,undefined
[4] Ltd,undefined
[5] Biomarkers and Personalized Medicine,undefined
[6] Core Function Unit,undefined
[7] Eisai Co.,undefined
[8] Ltd,undefined
[9] Biomarkers and Personalized Medicine,undefined
[10] Core Function Unit,undefined
[11] Eisai Inc.,undefined
来源：
British Journal of Cancer | 2014年 / 110卷
关键词：
triple negative breast cancer; eribulin mesilate; EMT/MET; metastasis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1497 / 1505
页数：8
相关论文
共 50 条
  • [1] Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states
    Yoshida, T.
    Ozawa, Y.
    Kimura, T.
    Sato, Y.
    Kuznetsov, G.
    Xu, S.
    Uesugi, M.
    Agoulnik, S.
    Taylor, N.
    Funahashi, Y.
    Matsui, J.
    BRITISH JOURNAL OF CANCER, 2014, 110 (06) : 1497 - 1505
  • [2] Eribulin mesylate suppresses experimental metastasis in the MX-1 human breast cancer model by reversing phenotypic states between epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET).
    Yoshida, Taku
    Kuznetsov, Galina
    Kimura, Takayuki
    Sugi, Naoko H.
    Shimizu, Hajime
    Ozawa, Yoichi
    Sato, Yoshiaki
    Uehara, Taisuke
    Watanabe, Hideki
    Takahashi, Kentaro
    Matsuura, Kentaro
    Uesugi, Mai
    Toyama, Osamu
    Yanagimachi, Mamoru
    Funahashi, Yasuhiro
    Matsui, Junji
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [3] The Roles of Epithelial-to-Mesenchymal Transition (EMT) and Mesenchymal-to-Epithelial Transition (MET) in Breast Cancer Bone Metastasis: Potential Targets for Prevention and Treatment
    Demirkan, Binnaz
    JOURNAL OF CLINICAL MEDICINE, 2013, 2 (04) : 264 - 282
  • [4] MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression
    Bullock, Marc D.
    Sayan, Abdulkadir E.
    Packham, Graham K.
    Mirnezami, Alex H.
    BIOLOGY OF THE CELL, 2012, 104 (01) : 3 - 12
  • [5] MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer
    Raghav, Kanwal Pratap Singh
    Wang, Wenting
    Overman, Michael J.
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [6] Epithelial to mesenchymal transition (EMT) is not sufficient for spontaneous murine breast cancer metastasis
    Lou, Yuanmei
    Preobrazhenska, Olena
    Keller, Ulrich Auf Dem
    Sutcliffe, Margaret
    Barclay, Lorena
    McDonald, Paul C.
    Roskelley, Calvin
    Overall, Christopher M.
    Dedhar, Shoukat
    CLINICAL & EXPERIMENTAL METASTASIS, 2009, 26 (07) : 898 - 899
  • [7] Eribulin suppresses the epithelial mesenchymal transition through the regulation of microRNA expression in breast cancer
    Inomata, Yosuke
    Taniguchi, Kohei
    Arima, Jun
    Lee, Sangwoong
    CANCER SCIENCE, 2023, 114 : 2077 - 2077
  • [8] Mesenchymal-epithelial transition (MET) and epithelial-mesenchymal transition (EMT) are closely related to chemotherapy resistance of triple negative breast cancer
    Deng, X.
    He, J.
    Chang, H. R.
    CANCER RESEARCH, 2013, 73
  • [9] The rejuvenated scenario of epithelial–mesenchymal transition (EMT) and cancer metastasis
    Fanyan Meng
    Guojun Wu
    Cancer and Metastasis Reviews, 2012, 31 : 455 - 467
  • [10] Differential expression pattern of pancreatic cancer stem cells expressing epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET)
    Chopra, N. K.
    Jain, K.
    Mirza, R.
    Choudhury, K.
    Wajid, S.
    Choudhury, S.
    EUROPEAN JOURNAL OF CANCER, 2016, 54 : S25 - S26
12345